Companies: 10,795·Total market cap: $144.5T
BioELife Corp.

BioELife Corp.

LITHOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$941
P/E Ratio
52W High$0.0002
52W Low$0.000001
Overview

BioELife Corp.(LITH)股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · LITH · 截至 Jun 8, 2026

关键指标

EPS (TTM)$-0.22lith eps ttm · lith earnings per shareEarnings history
PE Ratio (TTM)lith pe ratio ttm · lith price to earningsPE Ratio deep dive
Revenue (TTM)0.00lith revenue ttm · lith annual revenueFull revenue history
Dividend Yield不分红does lith pay dividends · lith dividend yieldDividend history
Shares Outstanding2.6Mlith shares outstanding · lith floatShares outstanding history
Next EarningsTBAlith earnings date · lith next earningsEarnings history

财务快照

完整财报
FY 2018Revenue$0.00
201620172018
bioelife corp. revenue · lith revenue 2018
FY 2018Net Income-$336958.00▼ 36.42% YoY
201620172018
bioelife corp. net income · lith profit 2018
FY 2018EPS$-0.13▼ 30.00% YoY
201620172018
lith eps · bioelife corp. earnings per share 2018
TTM:Revenue: $0.00Net Income: -$589687.00EPS: $-0.22View income statement →

股票表现

完整历史
1D+0.00%
1W+0.00%
1M+0.00%
3M+0.00%
YTD+0.00%
1Y+0.00%
5Y-99.93%

关于 BioELife Corp.

CEOMichael Terpin
IPO DateAug 7, 2009
Employees1
CountryUS

BioELife Corp. Engaged in the cannabinoid industry, BioELife Corp. provides a comprehensive selection of products. Their offerings span a variety of items such as adult gummies and tinctures (both available in combo…

what is bioelife corp. · lith stock overview · bioelife corp. company profile · who is bioelife corp. ceo · lith OTC · bioelife corp. headquarters · bioelife corp. business segments

关于股票概览与关键数据

BioELife Corp.(LITH)是 Drug Manufacturers - Specialty & Generic 行业的 Healthcare 类公司,于 Aug 7, 2009 在 OTC 上市。截至最近交易日,LITH 股价为 $0.00,市值约为 $941。过去12个月累计回报 +0.00%,年初至今回报 +0.00%。

2018 财年 BioELife Corp. 营收 —。完整财务数据(营收历史、盈利、资产负债表)请使用上方标签页。

常见问题

截至最近一个交易日,BioELife Corp.(LITH)股价为 $0.00,在 OTC 上市,52周区间为 $0.00 – $0.00。

LITH 最新股价LITH quote todaylive ticker 实时行情
数据来源:Financial Modeling Prep最后更新:Jun 8, 2026本内容不构成投资建议